- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04459455
Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic
Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Elevations in state anxiety, when moderate and temporary, serve an adaptive function in pandemic contexts, facilitating health behaviors like self-protection and social distancing. However, for some people elevated state anxiety transitions to anxiety disorders, creating undue suffering and impairment. Nearly 33% of both Wuhan residents and Chinese citizens screened positive for generalized anxiety disorder during the COVID-19 pandemic, with uncontrollable, persistent COVID-19-related worries strongly predicting presence of GAD. Similarly, large surveys indicate that levels of anxiety symptoms are rising among United States citizens.
This finding aligns with a large body of literature indicating stronger perceived control over one's own anxiety buffers against a variety of anxiety disorders. Thus, in the context of COVID-19, there is a pressing need for materials that might strengthen perceived control over anxiety, thereby reducing risk for anxiety disorder onset. Ideally, such materials would (1) in no way undermine positive health behaviors, like social distancing, and (2) have capacity for broad-scale, immediate accessibility. Internet-based interventions may particularly valuable during the pandemic stage of COVID-19 due to the need for social distancing, and they have already scaled up to address needs in China. However, drop out from internet-based interventions can be up to 83% and intervention engagement is a frequent issue. Fortunately, single-session experiences (SSEs) can improve mental health related outcomes with similar effect sizes as multi-session therapies, and pilot data from our team suggests they can increase general perceived control (within-group dz = 0.70).
The goal of this project is to test a web-based platform where people can confidentially access and provide feedback on brief activities, called 'single-session experiences' (SSEs), which are about 8 minutes in length, entirely self-administered, and computer-based (Contain COVID Anxiety and Project Remain COVID Free). Previous activities following the same best practices as these experiences have been shown to be safe to complete; predicted significant reductions in psychological distress; and are entirely self-administered. We will recruit a weighted-probability sample of the United States through Prolific's online platform, N = 500. All data collected from the SSEs will be confidential, and the only identifiable information that will be recorded is the participants' Prolific ID to facilitate compensation, which will be deleted from the data after the compensation has been paid. Those that choose to complete the activities have the option to submit their advice to their peers and have it posted anonymously to the web-based platform. This will provide people with an option for an easily accessible activity designed to promote healthy coping skills and resilience in a welcoming environment through which they can learn with others and share experiences.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794-2500
- Stony Brook University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant's age is 18 years and older
Exclusion Criteria:
- Participant is younger than 18 years old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Contain COVID Anxiety SSI
Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response.
They then read testimonials from three other people from the US who have applied a 3-step action plan for coping more effectively with their anxiety.
The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
|
Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response.
They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety.
The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
|
|
Placebo Comparator: Remain COVID Free SSI
This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs.
Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
|
This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs.
Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Anxiety Control Questionnaire (ACQ) from Baseline to Immediately Post-Intervention
Time Frame: Baseline, immediately post-intervention, 2-week follow-up
|
ACQ is a 30-item questionnaire that measures an individual's level of agreement with a set of beliefs.
Each item is scored on a scale from 0 (strongly disagree) to 5 (strongly agree) based on how much the statement is typical of the individual.
The questionnaire measures domains of emotion control, threat control, and stress control, but only the emotion control scale (4 questions) will be used for the purposes of this study.
|
Baseline, immediately post-intervention, 2-week follow-up
|
|
Change in Generalized Anxiety Disorder-7 (GAD-7) from Baseline to 2-week follow-up
Time Frame: Baseline, 2-week follow-up
|
The GAD-7 asks participants to rate 7 statements based on how generally anxious they have felt over the past 2 weeks.
Participants rate the 7 statements on a 4 point scale ranging from 0 (Not at all) to 3 (Nearly every day).
Total score ranges from 0 to 21 with higher scores representing higher generalized anxiety.
|
Baseline, 2-week follow-up
|
|
Change in Activity Social Distancing Intentions - 3 item version (SOC-D) from Baseline to immediately post-intervention
Time Frame: Baseline, immediately post-intervention
|
As validated measures for social distancing intentions do not yet exist, the 3 questions used in this measure are derived from the standardized item bank provided by the Center for Disease Control.
The three questions ask participants to rate how long they believe others would be willing to engage in social distancing behaviors regarding large events, public spaces, and private gatherings.
Participants rate the 3 statements on a 4 point scale ranging from 1 (Less than a Month) to 4 (4 months or more).
Total score ranges from 4 to 12, with a higher score indicating greater levels of intention to socially distance.
|
Baseline, immediately post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
COVID-19 Related Questions
Time Frame: Baseline
|
Derived from the CDC COVID-19 Community Survey Question Bank, participants will be asked to report whether they have been tested for COVID-19, tested positive for COVID-19, and displayed symptoms of COVID-19 in the past week.
The questions also ask how the COVID-19 outbreak affected the participant in the past two weeks and if the children's schools are currently closed.
|
Baseline
|
|
Inventory of Depression and Anxiety Symptoms (IDAS)
Time Frame: Baseline
|
The IDAS is a screening tool for depression and panic disorder that asks people to rate how they have been feeling and acting in the past two weeks.
Only the dysphoria subscale will be used; the subscale consists of 10 statements which the participants rate on a 1 (Not at all) to 5 (Extremely).
Total score ranges from 10 to 50 for Dysphoria.
|
Baseline
|
|
Self Hate Scale (SHS)
Time Frame: Baseline
|
This brief measure asks participants to rate 7 statements measuring feelings of self-hatred on a 7-point Likert scale ranging from 1 (Not at all true for me) to 7 (Very true for me).
Total score ranges from 7 to 49 with higher scores indicating higher levels of self hate.
|
Baseline
|
|
Comprehension Questions
Time Frame: Immediately post-intervention
|
Two multiple choice questions developed for the purpose of the study to serve as a quality check that ensures participants comprehended the core messages of both interventions.
|
Immediately post-intervention
|
|
Everyday Discrimination Scale-Short version
Time Frame: Baseline
|
The 5-item measure assesses chronic and routine unfair treatment in daily life on a scale from 1 - 5, with a total score between 5 and 25
|
Baseline
|
|
Perceived Changes in generalized anxiety symptoms
Time Frame: 2-week follow-up
|
One question designed for use in this study.
Participants rate their perceived changes in levels of generalized anxiety symptoms over 2 weeks from 1 (Much less anxiety) to 5 (much more anxiety)
|
2-week follow-up
|
|
Activity Hand Washing Intentions - 3 item version (WASH-I)
Time Frame: Baseline, immediately post-intervention
|
This scale asks participants to rate 3 statements based on their intentions to engage in hand washing behaviors.
Participants rate the 3 statements on a 7 point scale ranging from 1 (Strongly Agree) to 7 (Strongly Disagree).
Total score ranges from 3 to 21, and will be reverse scored so a higher score indicates greater levels of intention to engage in recommended hand washing behaviors.
|
Baseline, immediately post-intervention
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB2020-00204
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
University of CalabriaNot yet recruitingAnxiety | Anxiety Disease | Anxiety and Distress | Public Speaking AnxietyItaly
-
Clinica Alemana de SantiagoUniversidad del DesarrolloRecruitingAnxiety | Induction of Anesthesia | Anxiety Preoperative | Technology Use | Child Anxiety | Anesthesia Care | Anxiety After SurgeryChile
-
Boston Medical CenterPatient-Centered Outcomes Research Institute; Boston University; Johns Hopkins... and other collaboratorsCompletedAnxiety Disorders | Anxiety | Anxiety Symptoms | Child Anxiety | Anxiety, Mild to Moderate | Pediatric Anxiety DisordersUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Abant Izzet Baysal UniversityRecruitingAnxiety | Parental AnxietyTurkey (Türkiye)
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiActive, not recruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Florida State UniversityRecruitingAnxiety | Generalized Anxiety Disorder (GAD) | WorryingUnited States
-
Institut National de la Santé Et de la Recherche...Active, not recruitingAnxiety Disorders | Anxiety | Anxiety and FearFrance
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
Clinical Trials on Contain COVID Anxiety SSI
-
Selcuk UniversityCompleted
-
Corporacion Parc TauliUnknown
-
National Institute of Medical Sciences and Nutrition...CompletedQuality of Life | Rheumatoid ArthritisMexico
-
University of OsloModum BadUnknown
-
Elif KabasakalCompleted
-
Consorci Sanitari de TerrassaInstitut Català de la Salut; Fundacio d'Investigacio en Atencio Primaria Jordi...RecruitingCOVID19 | ACE Inhibitors | ARB | Influenza Vaccination | Amantadine | Antihistamine AllergySpain
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedStress DisorderFrance, United Kingdom
-
Verinder SharmaWithdrawnPostpartum DepressionCanada
-
University Hospital, AntwerpCompletedHypersensitivity | Anaphylaxis | Allergic Reaction | Perioperative Complication | Immediate Hypersensitivity | Hypersensitivity, Drug | Anaphylactic ReactionBelgium